Home

KAREN A DAWES

CIK 1261506 · Chairperson of the Board · last filed 2026-05-18

KAREN A DAWES is a Chairperson of the Board who has filed 84 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for RGEN, was dated May 18, 2026. Across all open-market trades the lifetime net is −$18.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $15.6M across reported positions. 15 SEC filings were submitted jointly with PDL BIOPHARMA, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$15.56M

Companies

5

Total Filings

84

Lifetime Open-Market Net

-$18.21M

Filer Profile

Reported Address
579 BELLEVUE AVE
NEWPORT, RI 02840
Related Filers
PDL BIOPHARMA, INC. — 15 joint filings, latest 2008-04-30
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
RGEN Director 92,816 $167.60 $15.56M -$18.17M 51 2026-05-18
Barinthus Biotherapeutics plc. (VACC) Delisted Director 1,700 $5.00 $8.5K $28.9K 5 2025-06-11
Assertio Therapeutics, Inc (ASRT) Delisted Director 1,410 $23.50 $33.1K -$93.0K 4 2020-05-11
Assertio Therapeutics, Inc (DEPO) Delisted Director 12,867 — — $27.3K 17 2018-05-10
PDL BIOPHARMA, INC. (PDLI) Delisted Chairperson of the Board 2,250 — — $0 4 2008-04-30

Recent Filings

84 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-18 RGEN Grant (A) +995 $0 EDGAR
2025-12-18 RGEN Sell (S) −275 -$44.3K EDGAR
2025-12-17 RGEN Notice (144) −275 -$44.3K EDGAR
2025-06-11 Barinthus Biotherapeutics plc. (VACC) Delisted Grant (A) — $0 EDGAR
2025-05-19 RGEN Grant (A) +973 $0 EDGAR
2024-08-19 RGEN — — $0 EDGAR
2024-06-14 RGEN Exer (M) +2,953 $199.9K EDGAR
2024-05-20 RGEN Grant (A) +803 $0 EDGAR
2024-05-14 Barinthus Biotherapeutics plc. (VACC) Delisted Grant (A) — $0 EDGAR
2024-02-28 RGEN Mixed +3,626 $1.3K EDGAR
Showing 1–10 of 84
Page 1 of 9
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.